Elasmogen Limited
Aberdeen, United Kingdom
Dr. Obinna Ubah is Principal Scientist and Head of Translational Sciences (Immunology) at Elasmogen Ltd, where he leads the discovery and development of next-generation biologic therapeutics for autoimmune and inflammatory diseases. He directs Elasmogen’s translational pipeline, including its lead drug candidate ELN28 for psoriatic arthritis and hidradenitis suppurativa.
A UKRI Future Leaders Fellow in Industry, Dr. Ubah has built cross-sector collaborations with leading academic investigators, clinicians, CROs and industry partners to accelerate biomarker-driven, precision medicine approaches. He has also co-supervised PhD students and actively mentors early-career scientists, shaping the next generation of translational researchers.
With a strong track record in advancing preclinical drug candidates, forging strategic partnerships, and presenting at major international conferences, Dr. Ubah is recognised for combining scientific rigour with commercial insight to deliver innovative therapies to patients with high unmet need.
Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): No financial relationships with ineligible companies to disclose
